NASDAQ:CADL

Candel Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CADL

*Your capital is at risk

$8.80

+0.380 (+4.51%)

At Close: Jun 03, 2026

Candel Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 59.23. In total, the insiders bought 6.25M and sold 325.59K CADL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	59.23
● Buy	6.25M shares
● Sell	325.59K shares
80% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Feb 23, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 59.23. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (80% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 25, 2025 Buy	Common Stock A-Award	Schoch Charles Chief Financial Officer	C-Suite Officer	5 353 Value: $25.0K
Jun 25, 2025 Buy	Common Stock A-Award	Loggia Nicoletta Director	Director	2 141 Value: $10K
Jun 25, 2025 Buy	Common Stock A-Award	Nabel Gary J. Director	Director	5 353 Value: $25.0K
Jun 25, 2025 Buy	Common Stock A-Award	Barone Francesca Chief Scientific Officer	Officer	4 282 Value: $20.0K
Jun 25, 2025 Buy	Common Stock A-Award	Papa Joseph C Director	Director	64 239 Value: $300.0K
Jun 25, 2025 Buy	Common Stock A-Award	Papa Joseph C Director	Director	64 239 Value: $300.0K
Jun 25, 2025 Buy	Common Stock A-Award	Barone Francesca Chief Scientific Officer	Officer	4 282 Value: $20.0K
Jun 25, 2025 Buy	Common Stock A-Award	Nabel Gary J. Director	Director	5 353 Value: $25.0K
Jun 25, 2025 Buy	Common Stock A-Award	Loggia Nicoletta Director	Director	2 141 Value: $10K
Jun 25, 2025 Buy	Common Stock A-Award	Schoch Charles Chief Financial Officer	C-Suite Officer	5 353 Value: $25.0K
Jun 25, 2025 Buy	Common Stock A-Award	Martell Christopher Director	Director	111 349 Value: $520.0K
Jun 25, 2025 Buy	Common Stock A-Award	Manning Paul B Director	Director	1 070 663 Value: $5.00M
Jun 25, 2025 Buy	Common Stock A-Award	Tak Paul Peter Chief Executive Officer	CEO / President	42 826 Value: $200.0K
Jun 25, 2025 Buy	Common Stock A-Award	Tyagarajan Seshu Chief Technology Officer	Officer	5 353 Value: $25.0K
Jun 20, 2025 Buy	Stock Option (Right to Buy) A-Award	Schoch Charles Chief Financial Officer	C-Suite Officer	50 000 Value: $237.5K
Jun 20, 2025 Buy	Stock Option (Right to Buy) A-Award	Schoch Charles Chief Financial Officer	C-Suite Officer	50 000 Value: $237.5K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Benz Edward J. Jr Director	Director	14 240 Value: $70.3K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Gaeta Renee Director	Director	14 240 Value: $70.3K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Loggia Nicoletta Director	Director	14 240 Value: $70.3K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Manning Paul B Director	Director	14 240 Value: $70.3K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Martell Christopher Director	Director	14 240 Value: $70.3K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Nabel Gary J. Director	Director	14 240 Value: $70.3K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Nguyen Diem Director	Director	14 240 Value: $70.3K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Papa Joseph C Director	Director	14 240 Value: $70.3K
Jun 17, 2025 Buy	Stock Option (Right to Buy) A-Award	Papa Joseph C Director	Director	14 240 Value: $70.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CANDEL THERAPEUTICS, INC.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of hi...

Read Full Profile Here